Direxion Daily S&P Biotech Bull 3X ETF
LABU
33 hedge funds and large institutions have $70.4M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2024 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 14 reducing their positions, and 15 closing their positions.
47% more call options, than puts
Call options by funds: $121M | Put options by funds: $82M
0.92% less ownership
Funds ownership: 6.67% → 5.76% (-0.92%)
17% less capital invested
Capital invested by funds: $84.4M → $70.4M (-$13.9M)
20% less funds holding
Funds holding: 41 → 33 (-8)
50% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 14
53% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TAA
TB Alternative Assets
Grand Cayman,
Cayman Islands
|
+$10M |
| 2 |
TI
Tidal Investments
Milwaukee,
Wisconsin
|
+$1.83M |
| 3 |
JP Morgan Chase
New York
|
+$1.48M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.3M |
| 5 |
G
Gainplan
Bloomfield Hills,
Michigan
|
+$653K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$10.2M |
| 2 |
Jane Street
New York
|
-$9.92M |
| 3 |
Squarepoint
New York
|
-$3.11M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.19M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.97M |
LABU Hedge Fund Activity: Q1 2024 in Review
33 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q1 2024, worth a combined $70.4M — down 17% from $84.4M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of LABU and 7 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 7 added.
The largest buyer was TB Alternative Assets, opening a new position worth an estimated $10M. The largest seller was Morgan Stanley, cutting an estimated $10.2M.
- 33 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q1 2024, down from 41 in Q4 2023.
- Funds reported $70.4M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q1 2024, down 17% quarter-over-quarter.
- 7 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q1 2024 and 15 closed out, a net change of -8 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q1 2024 was TB Alternative Assets, an estimated $10M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q1 2024 was Morgan Stanley, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2024.